2023

• Schmitt et al. Quantification of evolved DNA-editing enzymes at scale with DEQSeq.
• Becker et al. Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma.
• Shankar NM et al. Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer.
• Nacasaki Silvestre R et al. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect in vivo.
• Kandalla PK et al. M-CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation.
• Ruhnke Let al. Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial.
• Weller JF et al. Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study.
• Peschke JC et al. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
• Glatte B et al. Teclistamab impairs detection of BCMA CAR-T cells.
• Heim C et al. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
• Ullrich E et al. Editorial: Translating NK cell scientific research to clinical product manufacturing.
• Fischer L et al. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
• Busch CJ et al. Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages.
• Platzbecker U et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
• Devillier R et al. Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.
• Kayser S et al. Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.
• Eckardt JN et al. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification.
• Platzbecker U et al. Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
• Eckardt JN et al. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification.
• Bauer K et al. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS.
• Schneider M et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS.
• Hysenaj L et al. CD150-dependent hematopoietic stem cell sensing of Brucella instructs myeloid commitment.
• Zapata Bonilla SA et al. Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa study.
• Rojo-Romanos T et al. Precise excision of HTLV-1 provirus with a designer-recombinase.
• Rewersdorf JP et al. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).
• Stahl M et al. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
• Sandoval Bojórquez DI et al. Correction to Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies.
• Sauta E et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.
• Itzykson R et al. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.
• Bornhäuser M. T cells reloaded after allogeneic HCT.
• Okonechnikov K et al. 3D genome mapping identifies subgroup-specific chromosome conformations and tumor-dependency genes in ependymoma.
• Hysenaj L et al. CD150-dependent hematopoietic stem cell sensing of Brucella instructs myeloid commitment.
• Zimmermann R et al. Discriminant Principal Component Analysis of ToF-SIMS Spectra for Deciphering Compositional Differences of MSC-Secreted Extracellular Matrices.
• Oberbach A et al. Four decades of experience of prosthetic valve endocarditis reflect a high variety of diverse pathogens.
• Graninger M et al. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients.
• Korovina I et al. Targeting integrin α2 as potential strategy for radiochemosensitization of glioblastoma.
• Eckardt JN et al. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.
• Chihara D et al. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience.
• Georgi JA et al. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.
• Braun T et al. Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency.
• Saleh HA et al. Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells.
• Rojo-Romanos et al. Precise excision of HTLV-1 provirus with a designer-recombinase.
• Mircetic et al. CRISPR/Cas9 Screen in Gastric Cancer Patient-Derived Organoids Reveals KDM1A-NDRG1 Axis as a Targetable Vulnerability.
• Mian et al. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia.
• Kronstein-Wiedemann et al. Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers.
• Nauber et al. Medical microrobots in reproductive medicine from the bench to the clinic.
• Bornhäuser et al. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
• Zhou at al. A Dynamic rRNA Ribomethylome Drives Stemness in Acute Myeloid Leukemia.
• Scheller et al. Engineering CD20 CARs with a Twist.
• Zeidan et al. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes.
• Baer et al. Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?
• Gainullina et al. Network analysis of large-scale ImmGen and Tabula Muris datasets highlights metabolic diversity of tissue mononuclear phagocytes.
• Eckardt et al. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.
• de Laval et al. C/EBPβ-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cells.
• Mai et al. Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
• Denkinger et al. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.

2022

• Schmitt aet al. Prediction of designer-recombinases for DNA editing with generative deep learning.
• Jentzsch et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation.
• Körper et al. One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.
• Janssen et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
• Othman et al. Overlapping features of therapy-related and de novoNPM1-mutated AML.
• Efficace et al. Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
• Blache et al. Potential solutions for manufacture of CAR T cells in cancer immunotherapy
• Sayed et al. Efficient correction of oncogenic KRAS and TP53 mutations through CRISPR base editing
• Ding et al. DNA methylation–independent long-term epigenetic silencing with dCRISPR/Cas9 fusion proteins
• Subramanian et al. Long-term culture-expanded alveolar macrophages restore their full epigenetic identity after transfer in vivo
• Rutella et al. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
• Kunadt et al. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
• Lansing et al. Correction of a Factor VIII genomic inversion with designer-recombinases
• Teipel et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR-T-cell treatment
• Seif et al. CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models
• Lock et al. Automated, scaled, transposon-based production of CAR T cells
• Platzbecker et al. Luspatercept in patients with non-transfusion dependent β-thalassaemia
• García-Guerrero et al. ATRA works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T-cells
• Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy
• Peng et al. ROR1-targeting switchable CAR-T cells for cancer therapy
• Röhnert et al. Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia
• Nagler et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: an ALWP/EBMT analysis
• Hayden et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
• Locke et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
• Saini et al. Neoantigen reactive T cells correlate with the low mutational burden in hematological malignancies
• Taube et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
• Garcia-Manero at al. Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
• Weidner et al. Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen-deficiency in mice
• Bethge et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
• Stubbins et al. Inflammation and myeloid malignancy: Quenching the flame
• Hartmann et al. Compartment-specific mutational landscape of clonal hematopoiesis
• Campos Ramos et al. The era of in vivo T cell engineering
• Jayavelu et al.  The proteogenomic subtypes of acute myeloid leukemia
• Eckardt et al. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
• Merz et al. Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma
• Mank et al. Efficacy and Safety of Enteral Recombinant Human Insulin in Preterm Infants: A Randomized Clinical Trial
• Hernández-Malmierca et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
• Braun et al. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia
• Xu et al. A Self-Assembled Matrix System for Cell-Bioengineering Applications in Different Dimensions, Scales, and Geometries
• Guedan et al. Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
• Kubasch et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO
• Donnadieu et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
• Hoersten et al. Pairing of single mutations yields obligate Cre-type site-specific recombinases
• Récher et al. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
• Eckardt et al. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
• Medler et al. CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism
• Komrokji et al. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
• Lückemeier et al. Global k off -rates of polyclonal T-cell populations merge subclonal avidities and predict functionality
• Božić et al. Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
• Zanotti et al. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
• Damaschin et al. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
• Nguyen-Le et al. Nanosensors in clinical development of CAR-T cell immunotherapy

2021

• von Bonin et al. Clonal hematopoiesis and its emerging effects on cellular therapies